Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts
- 11 November 2011
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 107 (2) , 351-358
Abstract
Bevacizumab is one of the rare drugs that could improve high-grade glioma outcome after failure of chemoradiotherapy. However, to date, there is no biomarker predictive for efficacy of bevacizumab therapy in terms of survival improvement for patients with high-grade glioma. We performed a retrospective analysis of clinical factors associated with patient survival using a training cohort of 110 consecutive patients treated with bevacizumab for recurrent high-grade glioma and an independent validation cohort of 109 patients. In the training cohort, 110 consecutive patients received bevacizumab-based therapy. The number of chemotherapy cycles delivered was 1,411. Median follow-up was 12 months. Thirty-four patients (31%) had objective partial response and 24% had stable disease on magnetic resonance imaging evaluation. Median progression-free survival (PFS) and overall survival (OS) were 4.3 and 9.2 months, respectively. On univariate analysis, among classical prognosis factors, only Karnofsky status ≥70% was associated with improved outcome. Surprisingly, patients with low bevacizumab dose intensity (P < 0.0001) and OS (16 vs. 6 months, P = 0.0002). On multivariate analysis, low bevacizumab dose intensity was the most significant independent prognostic factor of survival. Analysis of the validation cohort yielded similar results, externally validating this observation. This large retrospective study using two independent cohorts of high-grade glioma suggests that the currently recommended dosage of bevacizumab (5 mg/kg/week) is not optimal. Further prospective randomized trials using lower dosages are warranted.Keywords
This publication has 29 references indexed in Scilit:
- High-Dose Antiangiogenic Therapy for Glioblastoma: Less May Be More?Clinical Cancer Research, 2011
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastomaProceedings of the National Academy of Sciences, 2011
- Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysisBMC Cancer, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and miceNeuro-Oncology, 2010
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and IrinotecanJournal of Clinical Oncology, 2008
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: Effects on tumor growth and angiogenesis in human glioblastoma xenograftsNeuro-Oncology, 2003
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995